Souhaitez-vous accéder aux communiqués récents ?

Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial.

Les fonds permettront d’avancer dans la découverte de traitements potentiellement disruptifs, à action rapide, pour la dépression résistante aux traitements et d'autres troubles...

Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disordersFirst-in-class, non-addictive, non-hallucinogenic molecules...

Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs First start-up company from Argobio’s...

Charlotte, NC, May 29, 2025 (GLOBE NEWSWIRE) -- Caring.com, a leading senior living referral service and the nation’s top site for care reviews, published the results of its 2025 Senior Mental...

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Bipolar Disorder (Manic Depression)- Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers an extensive...

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective,...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of...

Dublin, April 10, 2025 (GLOBE NEWSWIRE) -- The "Mental Well-Being Supplements Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Mental Well-Being...